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Background/Objective. Sarcopenic obesity (SO) is a hidden condition of reduced lean soft tissue (LST) in context of excess adiposity.
SO is most commonly reported in older adults and both its risk and prevalence increase with age. A variety of body composition
indices and cut points have been used to define this condition, leading to conflicting prevalence and risk prediction. Here, we
investigate variability in the prevalence of SO in an adult sample of individuals with class II/III obesity (BMI ≥ 35 kg/m2) using
different diagnostic criteria. Methods. SO definitions were identified from a literature review of studies using dual-energy X-ray
absorptiometry (DXA) to assess LST. Demographics, anthropometrics, and body composition (byDXA)weremeasured in 𝑛 = 120,
86% female (46.9 ± 11.1 years). Results. LST was extremely variable in individuals, even with similar body sizes, and observed across
the age spectrum.The prevalence of SO ranged from 0 to 84.5% in females and 0 to 100% in males, depending upon the definition
applied, with higher prevalence among definitions accounting for measures of body size or fat mass. Conclusion. SO is present, yet
variable, in adults with class II/III obesity. Accounting for body mass or fat mass may identify a higher number of individuals with
SO, although risk prediction remains to be studied.
1. Introduction
Obesity is a complex chronic global disease affecting people
worldwide across all ages, sexes, ethnicities, and nationalities
[1]. Comparing body weight to height using body mass index
(BMI) allows for the classification of obesity into class I (BMI
30–34.9 kg/m2), class II (BMI 35–39.9 kg/m2), and class III
(BMI ≥ 40 kg/m2) [2] The prevalence of the highest obesity
class is of concern due to its association with poorer health
outcomes compared to lower BMI categories [1]. In 2013-
2014, class III obesity affected 5.5% of males and 9.9% of
females in the United States, with a linear increase in preva-
lence for females since 2005 [3]. Compared to the United
States, fewer Canadians have class III obesity (2.5%); however
the same trend by sex is found with a greater percentage of
females affected (3%, compared to 2% of men) [4, 5].
In addition to BMI, waist circumference can be used to
identify obesity. Both anthropometricmethods provide a sur-
rogate assessment of fat mass (FM) but are poor detectors of
leanmass, also called lean soft tissue (LST), and hence of body
composition. People with obesity can have varying propor-
tions of LST and the single use of anthropometry to diagnose
obesity precludes an accurate characterization of the different
proportions of FM versus LST of an individual [6].
Emerging evidence suggests obesity can coexist with low
LST (sarcopenia) [7–10]. In this case, the gravity impact of the
excess body weight may not be sufficient to promote a con-
current increase in LST; therefore, individuals with obesity
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may have high FM without a parallel increase in LST [11].
Notably, this phenotype termed sarcopenic obesitymay not be
identified without the use of body composition assessment
techniques. Low LST is an important prognostic factor in
health and clinical conditions, as its main component is
skeletal musclemass, a tissue of vital importance for strength,
functional mobility, immune function, and wound healing,
among others [8, 12–16].
Sarcopenia has been primarily studied in older adults and
individuals with chronic conditions but emerging evidence
suggests that “healthy,” younger individuals are also at risk for
presentingwith this condition [17, 18]. Compoundedwith the
consequences of excess FM, the concurrent sarcopenic obe-
sity phenotype has been independently associated with worse
morbidity and disability than either sarcopenia or obesity
alone [10]. In the context of obesity treatment, weight loss
results in the loss of both FM and LST [19, 20]. With
repeated weight loss-gain cycles combined with age-related
body composition changes, developing sarcopenic obesity is
possible [10].
The identification of sarcopenic obesity is limited not only
due to the availability of accurate body composition tech-
niques but also due to heterogeneity in its diagnostic criteria
[10]. A variety of body composition indices and cut-offs
have been used to define sarcopenia and obesity, leading to
conflicting findings on the prevalence and risk prediction
of this condition [10, 21] Additionally, the great majority of
studies have focused on identifying sarcopenic obesity in
older adults and the prevalence within younger adults and
those with class II/III obesity is not well defined. With the
increasing prevalence of class III obesity [3] and of sarcopenia
[18], the prevalence of sarcopenic obesity in these individuals
is likely to increase dramatically. Therefore, the objective of
this study is to explore the variability in the prevalence of
sarcopenic obesity in an adult sample with class II/III obesity
using different diagnostic criteria.
2. Methods
In a cross-sectional approach, we included consecutive pa-
tients from a multidisciplinary clinic providing medical and
bariatric surgical interventions for adults (18–69 years) with
class II/III obesity (BMI ≥ 35 kg/m2) in Edmonton, Alberta,
Canada. Ethics approval was received from the University of
Alberta Health Research Ethics Board.
Medical records were used to assess demographic and
medical history obtained from the initial clinic assessment.
Height was measured (without shoes, within 0.1 cm) with
a wall-mounted stadiometer. Weight was measured (single
layer of clothing, without shoes, within 0.1 kg) with a high-
capacity weigh scale (Scale-Tronix 6702W, WelchAllyn Inc.,
Skaneateles Falls, New York). Waist circumference was mea-
sured (within 0.1 cm) with a nonstretch tape at the midpoint
of the torso (between lowest rib and iliac crest) on the right
side using a cross-handed technique, recorded as the average
of three consecutive measures.
Dual-energy X-ray absorptiometry (DXA) was required
at the initial assessment and completed at a local medical
imaging center [Hologic Discovery A (S/N 45026) or W (S/
N 83792) scanners, software version 12.7.4.2, Hologic Inc.,
Bedford MA]. No subjects exceeded the DXA weight capac-
ity limit (204 kg) or scan area length (195 cm). Reflection
positioning was used for subjects with larger supine widths
(>65 cm). Right side data was duplicated when values for the
left side were either not reliable or available [22–24]. Col-
lected values included whole body and segmental values for
FM, LST, appendicular skeletal muscle mass (ASM, which is
LST from arms and legs), and fat-free mass (FFM = LST +
bone), and its derivatives are adjusted by height in square
meters, also called indexes (e.g., FMI, ASMI). Detailed defi-
nitions of each of these body composition variables can be
found elsewhere [6].
Subjectswith complete initial clinic assessments and body
composition analysis by DXA were included in the study.
DXA scans available for analysis dated from January 2009
to June 2012, after which they were no longer ordered at the
initial clinical assessment. All data was collected prior to
starting obesity treatment. Subjects were excluded from the
final analysis if DXA data was unreliable (i.e., segmental
measurements were outside of the field of view or due to lack
of separation of tissues between the arms and torso).
2.1. Sarcopenic Obesity: Definitions and Terminology. A liter-
ature search was conducted using PubMed, Scopus, andWeb
of Science databases to identify studies using definitions sar-
copenic obesity based upon body composition data derived
from DXA with or without use of anthropometric variables
(e.g., weight, BMI, and waist circumference), excluding clini-
cal studies (e.g., cancer). For definitions using ethnic-specific
cut points, white/Caucasian references were included as the
majority of our population (83.9% Edmonton, 86% Canada)
self-identified as Caucasian [25]. Ethnicity was not collected
as part of the clinic assessment, in accordance with the
Freedom of Information and Protection of Privacy Act [26],
therefore unavailable for analysis.
Based on the literature review, ten studies were identified
using nine variables based upon LST or ASM to define sar-
copenia (Table 1) and four variables were identified to define
obesity (Table 2, plus FMI phenotype listed in Table 1) [7, 8,
18, 27–33].
The use of inconsistent body composition terminology
may preclude a clear understanding of sarcopenic obesity’s
diagnostic criteria in the literature (i.e., authors use of differ-
ent terminology for the same body composition variables).
Therefore, in order to improve clarity while still accurately
representing the body composition components being mea-
sured in each study, we consistently use the terms LST for
studiesmeasuring the nonbone, nonfat body compartment in
general from thewhole body (i.e., arms, legs, trunk, and head)
and ASM for studies measuring LST from the arms and legs
[6].
With the exception of BMI, each variable for sarcopenia
and obesity used sex-specific cut points, with more than
one cut point for some variables. Sixteen unique definitions
(composed of a variable and cut point for each sarcopenia
and obesity) were identified and applied to the sample to
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Table 2: Prevalence of obesity in study cohort (𝑛 = 120) using various sex-specific definitions determined by anthropometric and dual-energy
X-ray absorptiometry measurements amongst studies investigating sarcopenic obesity.
Variables Reference Females (𝑛 = 103) Males (𝑛 = 17)
Cut point Prevalence (%) Cut point Prevalence (%)
BMI (kg/m2) Newman et al., 2003 [29] ≥30 100 ≥30 100
Oh et al., 2015 [32]
Waist circumference (cm)a Levine and Crimmins, 2012 [31] >88 100 >102 100
Fat mass (%) Kim et al., 2009 [28] >31.71 100 >20.21 100
Bouchard et al., 2009 [30] ≥35 99 ≥28 100
Batsis et al., 2015 [8] ≥35 99 ≥25 100
Baumgartner et al., 1998 [7] >38 99 >27 100
Baumgartner et al., 2004 [37] >40 98 >28 100
Zoico et al., 2004 [27] >42.9 90.3 NA
aWaist circumference not available for the entire cohort: females (𝑛 = 81, 78.6%) and males (𝑛 = 13, 76.5%). BMI: body mass index; NA: not applicable.
explore the prevalence of sarcopenic obesity. Linear regres-
sion analysis with ASM, height, and FM (kg) was used to
determine prevalence of sarcopenia using the Newman et al.,
residual method [29].The classification by body composition
phenotypes was determined using deciles of population-
derived ASMI and FMI cut points based on sex, BMI, and
age, as per the protocol described in Prado et al. [18]. The
classification of abnormal body composition phenotype as
a load-capacity model (load being FM and capacity FFM)
was calculated as the ratio of FM : FFM (as centiles), as per
methodology described in Siervo et al. [33].
Additional classifications were derived from our study
cohort, using ASMI calculated as the lowest 20th percentile
and two standard deviations (SD) below the mean of the
distribution; a method commonly reported in the literature
when a reference population is not available [34]. Definitions
of sarcopenic obesity utilizingmeasures ofmuscle strength or
function were not included, as data were not available for our
cohort.
2.2. Statistical Analysis. Descriptive statistics were used for
subject characteristics, anthropometrics, and body composi-
tion and reported as mean (interquartile range). Normality
testing was completed using the Shapiro-Wilk test. Frequen-
cies and proportions were reported for categorical variables.
Independent samples t-test for normally distributed data and
nonparametric (Mann–Whitney U) independent samples
t-test were used to compare variables between sexes. To
account formissing data (waist circumference), subjects were
compared to determine if differences existed between the
groups. Correlations were tested using Pearson’s r to explore
the relationship between variables. Two-tailed tests were used
for all the analysis with a 𝑝 value of <0.05 considered for
statistical significance. Data was analysed using IBM SPSS
Statistics for Mac, version 23 (IBM Corp., Armonk, NY,
USA).
3. Results
A total of 167 subjects with completed initial assessments
and DXA scans were initially reviewed, in which 120 subjects
(85.8% female) had reliable DXA data to be included in the
final analysis. Clinical characteristics of excluded subjects
(𝑛 = 47) were not different from those included in the analy-
sis. Mean age of the entire cohort was 46.9±11.1 years (range:
18–69 years). Subject characteristics, anthropometrics, and
body composition are presented in Table 3.
Patients were community-dwelling (100%) and predom-
inantly married/common-law (F 68%, M 65%) and worked
outside the home (F 68%, M 70%) and 7.8% of females (no
males) were current smokers. The majority of patients were
generally well educated (F 98%, M 94% completed high
school), with more females than males who completed their
education at a university/college level (F 57%, M 35%).
Recommended activity levels (>150 minutes of moderate
intensity activities a week) were met by 20% of females and
23% of males.
Due to the positively skewed data for weight in females,
some variables were not normally distributed. Independent
samples t-tests and nonparametric (Mann–Whitney U) tests
results were compared and showed the same results. No
significant differences were observed between females and
males for age, BMI, and FM (kg), Table 3. Compared tomales,
females had higher values for FM (%), FMI, and FM : FFM
ratio and lower values for variables depicting the lean mass
compartment. A large variability in LST (kg)was observed for
individuals with the same body size, Figures 1(a) and 1(b).The
relationship between BMI and LST in females and males was
moderate and weak (R = 0.41, R = 0.20, resp.), Figure 1(a).
The entire cohort met the criteria for obesity defined by
BMI, waist circumference, and FMI cut points (Table 2). For
FM%, all males exceeded the five different cut points. One
female (BMI 39.7 kg/m2 and 32.2% FM) did not meet the
criteria for obesity defined by % FM with five of the six
different cut points. Ten females (9.7%) had % FM below
the highest cut point (42.9%) and therefore would not be
identified with obesity despite BMI’s ranging from 35.9 to
45.1 kg/m2. Of note, the highest sex-specific 20th percentile
for FMI was >23.8 kg/m2 for females and >21.5 kg/m2 for
males.
Considering the entire cohort had class II/III obesity as
defined by BMI, when each definition of sarcopenia was
Journal of Nutrition and Metabolism 5
Table 3: Subject characteristics, anthropometrics, and body composition (𝑛 = 120), by sex.
Variablesa Females (𝑛 = 103) Males (𝑛 = 17) p value
Mean (IQR) Mean (IQR)
Age (years) 46.5 (18) 49.4 (10) 0.352
Anthropometrics
Height (cm) 164.1 (8.3) 177.2 (9.7) <0.0001
Weight (kg) 117.3 (25.8)b 138.2 (24.9) <0.0001
BMI (kg/m2) 43.5 (8.4)b 44.0 (6.3) 0.960
Waist (cm)c 120.4 (18.2) 141.0 (15.3) <0.0001
Body composition
Fat mass (kg) 55.6 (16.8)b 56.5 (17.5) 0.759
Fat mass (%) 48.0 (5.7) 41.4 (8.3) <0.0001
FMI (kg/m2) 20.6 (5.1)b 18.0 (6.0) 0.009
FM : FFM ratio 0.9 (0.2) 0.7 (0.2) <0.0001
LST (kg) 57.1 (9.3)b 76.2 (13.9) <0.0001
LSTI (kg/m2) 21.2 (2.6)b 24.2 (3.9) <0.0001
LST by weight × 100 (%) 49.0 (6.4) 55.4 (9.1) <0.0001
ASM (kg) 24.7 (4.8)b 34.2 (7.3) <0.0001
ASMI (kg/m2) 9.2 (1.6) 10.9 (2.3) <0.0001
ASM by weight × 100 (%) 21.2 (2.9) 24.9 (5.3) <0.0001
ASM by BMI 0.57 (0.1)b 0.78 (0.2) <0.0001
aTerminology for variables is selected for consistency and may differ from terms used by original authors. bVariable not normally distributed. cWaist
circumference not available for the entire cohort: females (𝑛 = 81, 78.6%) and males (𝑛 = 13, 76.5%). IQR: interquartile range; BMI: body mass index; FMI: fat
mass index; FM: fat mass; FFM: fat-free mass; LST: lean soft tissue; LSTI: lean soft tissue index; ASM: appendicular skeletal mass; ASMI: appendicular skeletal
mass index.
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Figure 1: Variability of lean soft tissue by (a) body mass index (BMI) and (b) weight in adults with class II/III obesity (𝑛 = 120, females =
103). The box illustrates selected examples of females with (a) the same BMI (40 kg/m2) but LST varying from 41.2 to 74.9 kg and (b) same
weight (116 kg) but LST varying from 52.9 to 74.9 kg.
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applied to the current sample, the prevalence of sarcopenic
obesity varied from 0 to 84.5% for females and 0 to 100% for
males (Table 4). Definitions using unadjusted values for LST,
ASM, or ASMI, with the exception of the highest ASMI cut
point, failed to identify any subjects with sarcopenic obesity.
Notably, a higher prevalence of sarcopenic obesity was iden-
tified by definitions combining ASM either with weight, BMI,
or a measure of FM.
The sex-specific cut points developed from the Newman
et al. [29] study group were only able to identify males
with sarcopenic obesity in our cohort, Table 4. Applying the
Newman et al. [29] residual method to derive cut points from
the current cohort, sarcopenic obesity was identified in both
sexes. For the latter, the cohort-specific cut points derived
from the 20th percentile of the sex-specific distributions of
the residuals were <2.96 for females and <−4.82 for males,
identifying 19.4% of females and 17.6% of males with sar-
copenic obesity.
Equivalent cut points for ASMI were also derived from
the study cohort. The cohort-specific 20th percentile cut
point to describe sarcopenic obesity by ASMI was <8.21 kg/
m2 for females and <9.44 kg/m2 for males. Using the lowest
2 SD criteria for ASMI, the cohort-specific cut points were
<6.79 kg/m2 for females and <8.62 kg/m2 for males. Selecting
the cohort-specific 20th percentile, low ASMI was observed
across the age spectrum, Figure 2.
Using the phenotype definition proposed by Prado et al.
[18] to the entire sample, 16 (13.3%) subjects where classified
with high adiposity and low muscularity (sarcopenic obese-
like phenotype), and 95 (79.2%) subjects presented with the
high adiposity and high muscularity phenotype (obese
nonsarcopenic-like phenotype), Figure 3. Nine females were
classified as having a normal body composition phenotype.
Using the load-capacity model to account for the inter-
action of both body compartments [33], the FM : FFM ratio
identified about a third of females and three-quarters ofmales
with moderate and severe body composition phenotype
(≥85th percentile), Table 4.
4. Discussion
Previous research identified sarcopenic obesity in older adults
[35] and groups with certain chronic diseases [6]. Although
several diagnostic criteria have been used, no one approach
has been widely accepted. This is the first study to use state-
of-the-art methodology (DXA) to explore the prevalence
of sarcopenia in a younger adult cohort (mean age 46.9 ±
11.1 years) with class II/III obesity. LST was extremely
variable in individuals with similar BMI illustrating a wide
variability of body composition within the same body size.
Using 16 previously reported definitions, the prevalence of
sarcopenic obesity varied from zero to 100%. Such variability
precludes a comprehensive understanding of the prevalence
of sarcopenia in younger individuals withmore severe classes
of obesity, as well as the development of preventive and
treatment strategies for this condition in clinical settings.
As these individuals are actively seeking obesity treatment,
maintaining leanmass should be a coprimary endpoint of the
nutrition care plan together with weight management.
All males and almost all females were classified with
obesity using diverse FM% cut points (30–42.9% for females
and 20–29% for males). Most individuals with a BMI ≥
35 kg/m2, excluding extremely muscular individuals, will
present with excess adiposity [36] and prevalence will vary
only based on the comparison cohort used to identify the cut
point. For example, 10 females from our cohort would not be
considered to have obesity using the Zoico et al. [27] cut
point based on quintiles of % FM from a sample of healthy
elderly females (BMI 26 ± 3.8 kg/m2). Nonetheless, these 10
females were within 0.2% to 3.7% below the % FM cut point.
Interestingly, using the adjusted Prado et al. cut points [18],
we observed that nine females were not classified as having
high adiposity. In addition to sex, this cut point is notably
adjusted for age and BMI. Six females were identified as
having both lower % FM and FMI using the Zoico et al. [27]
and Prado et al. [18] cut points respectively.
Prevalence of sarcopenia ranged approximately from 0 to
84.5% in females and from 0 to 100% in males. The null
prevalence using several cut points may be explained by
the approach used to define sarcopenia. Reference values
to diagnose sarcopenia have been primarily developed from
older cohorts, which may not be applicable for younger
adults. Although Cherin et al. [17] included younger indi-
viduals (45–83 years), their cohort’s mean age was 63.1 ±
10.2 years and the prevalence of sarcopenic obesity was not
reported.
In our study, no subjects were identified with sarcopenic
obesity by definitions of LST [27, 28]. Baumgartner et al.
[7, 37] and others have defined sarcopenia using ASMI sex-
specific cut points based on two standard deviations below
the mean for a young reference group [7, 21, 30, 37–39].
No subjects were identified with sarcopenic obesity applying
each of these different cut points. Although these young
reference groups were North American and of similar age to
the current study cohort, their BMI (described as “normal”)
would be much lower. However, sarcopenic obesity may still
be present but not identified as the cut points may not be
sensitive enough to identify relatively low lean mass in sub-
jects with larger total body mass. Likewise, no subjects were
identified as sarcopenic using Newman et al. cut point which
defined sarcopenia as the lowest 20th percentile of their
cohort’s ASMI distribution [29]. Notably, applying the same
method to our cohort, our ASMI cut points were 45% and
31% greater for females and males, respectively, highlighting
how differences in age and body size may impact comparison
among different cohorts.
Although the quantity of LST may meet or exceed refer-
ence values derived from normal, healthy reference popu-
lations (e.g., normal BMI or age 25 years), the higher LST
amount is insufficient tomaintain the larger body size (largely
due to a larger FM amount). This phenomenon can be
conceptualized as the metabolic load (due to FM) versus
capacity (of the LST/FFM) model previously described [33].
Therefore, sarcopenia in those with obesity may be present at
higher LST values and must be evaluated in relation to body
mass or FM.
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Figure 2: Variability of appendicular skeletal mass index (ASMI) by
age (23–69 years) in adults with class II/III obesity (𝑛 = 120, females
= 103). The line indicated the 20th percentile of ASMI for females;
subjects below this level ranged in age from 24 to 69 years.
Our findings support the use of a combined definition of
body mass or FM to a measure of sarcopenia for the identifi-
cation of sarcopenic obesity in this cohort of younger adults
with class II/III obesity. Considering measures of ASM with
weight [31, 32], BMI [8], FMI [18], or FM [29, 33], our preva-
lence of sarcopenia ranged from 12.6 to 84.5% for females and
17.6 to 100% for males. Likewise, in the Newman et al. [29]
study, higher prevalence rates were observed for both sexes
using a method in which ASM was considered in relation to
height and FM compared to none using nonadjusted ASMI
cut points. The authors concluded this technique captured
the effect of both LST (as ASM) and high FM simultaneously,
therefore identifying a greater proportion of people with
obesity as being sarcopenic. Our findings are consistent with
their results and highlight the potential importance of con-
sidering FM with LST indices together when evaluating
sarcopenia in people with obesity.
We were able to identify three body composition pheno-
types using the Prado et al. [18] previously established cut
points, where age, sex, and BMI-specific reference curves
were created to define body composition phenotypes (FMI
and ASMI above or below the 50th percentile). As the 50th
percentile was used, the terms “obesity” and “sarcopenia”
were avoided with individuals being classified using a com-
bination of high/low adiposity and high/low muscularity.
The concurrent high adiposity and low muscularity are the
“sarcopenic obesity-like” phenotype with an observed pop-
ulation prevalence of 10.3% in females and 15.2% in males.
Although subjects >136 kg were excluded from that study
thereby limiting the reference data, applying this method to
the current study cohort produced similar results, identifying
Low adiposity
High muscularity High muscularity
8.7% females
0% males
High adiposity
78.6% females
82.4% males
Low adiposity
Low muscularity Low muscularity
0% females
0% males
High adiposity
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Figure 3: Body composition phenotype, by decile groups of appen-
dicular skeletal mass index (ASMI) and fat mass index (FMI), for
adults with class II/III obesity (𝑛 = 120, females = 103) [18].
12.6% of females and 17.6% of males with sarcopenic obesity.
Similar to Siervo et al. [33] FM : FFM ratio reference curves
in our study found females had a higher FM : FFM ratio
than males. Notably, the current study included subjects with
higher weights, with 17.5% of females and 41.2% of males
>136 kg. The load-capacity model is a novel method to iden-
tify low LST relative together with excess FM in subjects with
class II/III obesity.
Although our sample size of males was small, their preva-
lence of sarcopenia was higher than females for all definitions
except the Newman et al. residual method [29], where the
prevalence was similar.The prevalence of sarcopenia by sex is
controversial with some studies reporting higher prevalence
among males, others among females and some finding no
differences [35].
An important consideration for any definition is to
understand the characteristics of the group from which the
cut points were derived. Notably, some definitions were
developed from European or Asian cohorts that are ethni-
cally different from a North American population. Widely
recognized differences in body composition among different
ethnicities preclude a direct comparison of sarcopenic obesity
prevalence among different studies.
In the absence of a young reference group, cohort-specific
cut points were used using the lowest one [30] or two [28, 29]
quintiles forASMI.Applying this approach to our dataset, our
cohort-specific cut points were much higher than previously
published ones, again highlighting that cut points derived
from other cohorts or nonspecific populations (i.e., older
adults, individualswithout obesity)may either fail to detect or
underestimate the prevalence of sarcopenic obesity in adults
with class II/III obesity. Contrary to expectations, the preva-
lence of sarcopenia was not higher among individuals ≥65
years compared to those <65 years [18]. Indeed, we reported
ASMI was highly variable across the age spectrum; only
one of the 23 individuals with an ASMI below the 20th
percentile for this cohort was older than 65 years (Figure 2).
The large variability of LST (Figures 1(a) and 1(b)) in
individuals with the same body size represents a clinical chal-
lenge for determining nutritional requirements. For exam-
ple, protein and energy needs are often determined based
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on body weight, yet, considering lean mass drives protein
requirements, people with the same body weight can receive
varying amounts of protein per unit of leanmass (LST), a con-
cept previously explored [40, 41]. In the selected example on
Figure 1(b), if protein requirements were assessed as 1 g/kg
actual body weight (116 kg), the estimated amount of dietary
protein would be equivalent to 1.6 to 2.2 g/kg LST.
Data on body composition of adults with class II/III obe-
sity is limited, especially of those with BMI > 40 kg/m2. One
barrier is related to equipment limitations [42]. Individuals
with class III obesity not only have increased weights, but
increased body dimensions such as height or supine width.
Although there are large body composition data sets available,
subjects above 136 kg were excluded due to equipment limi-
tations [36]. Recent DXA equipment improvements, such as
the Lunar iDXA (GE Healthcare) and Discovery/Horizon
models (Hologic, Inc.), have increased scan area widths and
weight capacities, improving the capability to assess more
people with obesity.
Notably, this study was completed prior to initiation of
obesity treatment at the clinic. Weight loss is associated
with reductions in both FM and LST, with weight regain
predominately as FM [10]. If people with low LST are not
identified as such, initiating obesity treatments targeted to
reduce weight can further reduce LST, thereby either creating
or worsening a sarcopenic state.
Limitations of our study include our ambulatory cohort
seeking obesity treatment, which may not reflect all adults
with obesity or other care settings (i.e., acute care, long
term care). Although the representation of males in the
current study appears low, it is comparable to other studies
conducted in this clinic [43, 44]. In general, males tend to be
underrepresented in obesity treatment studies [45, 46]. Addi-
tionally, we were unable to explore definitions of sarcopenia
using a measure of muscle function, as these were not
collected as part of patient’s initial assessment.
5. Conclusions
Sarcopenia was present in our cohort but masked by obesity.
Basic anthropometric measurements alone are inadequate to
identify sarcopenia and hence sarcopenic obesity in these
individuals. Sophisticated tools such as DXA may be needed
to identify and profile LST of adults with class II/II obesity
and could be implemented as part of clinical assessment. The
inclusion of measures of FM and body size in the defini-
tion of sarcopenic obesity identifies a greater proportion of
individuals with this abnormal body composition phenotype
compared to stand-alone definition of low lean mass. Differ-
ent diagnostic criteria should be tested in prospective studies
investigating the risk prediction for metabolic, functional,
and clinical parameters of these adults with class II/III
obesity.
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